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The environmental release of engineered microorganisms has caused health and environmental concerns. In
this study, an animal model was used to examine health effects following pulmonary exposure to environmental
and clinical isolates. In order to rule out the possibility that an adverse response was caused by endotoxin, 50%Yo
lethal doses (ID50) were determined, when possible, with endotoxin-sensitive (C3HeB/FeJ) and endotoxin-
resistant (C3H/HeJ) mice by using both environmental isolates (Pseudomonas aeruginosa BC16, BC17, BC18,
and AC869 and Pseudomonas maltophUia BC6) and clinical isolates (P. aeruginosa PAO1 and DG1). The LDIo
of strains AC869, DG1, and PAO1 are 1.05 x 107, 6.56 x 106, and 1.02 x 107 CFU, respectively, in C3HeB/FeJ
mice and 1.05 x 107, 1.00 X 107, and 2.75 x 106 CFU, respectively, in C3H/HeJ mice. Strains BC17 and BC18
were not lethal to the animals. On the basis of the LDI50 data, an appropriate sublethal dose (approximately 106
CFU) was selected. Animals were challenged intranasaily with microorganisms, and clearance from the lungs
and nasal cavity was determined. Strains BC17, BC18, and AC869 were not detected in lungs or nasal washes
14 days following treatment. Strains BC6, BC16, and DG1 were recovered from the nasal cavities at the end
of the experiment. Only strain PAO1 was detected in lungs and in nasal cavities 14 days after treatment. At
selected intervals following treatment, the percentages of polymorphonuclear leukocytes and lymphocytes in
bronchoalveolar lavage samples were determined. P. aeruginosa AC869, PAO1, and DG1 elicited a relatively
strong inflammatory response which was indirectly related to lung clearance. An intermediate response was
observed in the lungs of animals challenged with P. malophUia BC6 and P. aeruginosa BC16 and BC17. A
significant increase in the ratio of lung weight to body weight was observed in strain AC869-treated animals.
Our data indicate that upon intranasal exposure P. aeruginosa AC869 has the potential to induce adverse health
effects in mice, as shown by lung and nasal cavity clearance and the pulmonary inflammatory response.
Members of the genus Pseudomonas are used for environ-
mental applications because of their effectiveness in biocon-
trol and versatile substrate utilization abilities. For example,
an engineered strain of Pseudomonas syringae has been
shown to be useful in the prevention of ice nucleation on
crops (22). The delta endotoxin genes from Bacillus thuring-
iensis have been introduced into Pseudomonas fluorescens
for more effective delivery of the pesticidal activity (29).
Other pseudomonads, such as Pseudomonas cepacia and
Pseudomonas putida, can be used as fungicides for winter
wheat (9). Pseudomonads can metabolize a variety of com-
pounds introduced into the environment, such as petroleum
products (20). Even though most of these microorganisms
are generally considered harmless soil isolates, there is
potential for adverse health effects due to exposure to high
concentrations of microbial products during production or
environmental application (30).
Pseudomonas aeruginosa is recognized as an opportunis-
tic human pathogen and is capable of causing disease espe-
cially in immunosuppressed hosts and patients with leuke-
mia or cystic fibrosis (4, 5, 15, 36). P. cepacia is involved in
nosocomial infections (24) and can colonize and cause
pneumonia and septicemia in cystic fibrosis patients (33). P.
putida, P. fluorescens, and Pseudomonas maltophilia (Xan-
thomonas maltophilia) have been shown to cause secondary
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infections in cancer patients and are involved in other
opportunistic infections (13).
Adverse effects from pulmonary exposure to pseudomon-
ads can be attributed to a variety of pathogenicity factors.
The pathogenicity factors include extracellular toxins, such
as phospholipase, elastase, and toxin A (23, 45), and adhes-
ins, such as exoenzyme S (1) and pili (47). Alginate produc-
tion can occur in isolates obtained from cystic fibrosis
patients and can cause a chronic infectious state; this per-
sistence has been linked to decreased production of viru-
lence factors (46). Except for alginate production, there is no
distinction between clinical and environmental isolates in the
expression of virulence factors (28), serotypes (19), or outer
membrane proteins (16).
Pulmonary exposure to endotoxin, a component of the
gram-negative cell wall, also can result in negative health
effects. Research has determined that endotoxin causes
fever, increased permeability (3), acute bronchoconstriction
(34), an influx of macrophages (27), and release of tumor
necrosis factor that can cause shock and death in humans
(25, 42). Endotoxin has been shown to promote translocation
of microorganisms from the gastrointestinal tract to the
mesenteric lymph nodes, spleen, and liver, predominantly in
gnotobiotic and antibiotic-treated mice (2).
Both rat (6, 14, 18, 39) and mouse (12, 39, 41) models have
been used to study health effects following pulmonary expo-
sure to pseudomonads. Intranasal exposure and intratra-
cheal exposure have been used in a reproducible surrogate
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TABLE 1. Doses, selective agents, and strains used in this study
Clearance Inflammatory
Strain dose response Selective Refer-
(CFU, 106) (CFU 1o6) agent ence
P. maltophilia BC6 2.60 2.00 Kanamycina 11
P. aeruginosa BC16 1.21 1.00 Ampicillinb 11
P. aeruginosa BC17 0.76 1.20 11
P. aeruginosa BC18 0.83 1.20 Ampicillin 11
P. aeruginosa AC869 1.74 1.40 Kanamycin 8
P. aeruginosa PAO1 1.41 1.20 Ampicillin 17
P. aeruginosa DG1 1.49 1.50 Ampicillin 47
a Kanamycin was added to Pseudomonas isolation agar at a concentration
of 50 ,ug/ml.
b Ampicillin was added to Pseudomonas isolation agar at a concentration of
50 SLg/ml.
infection model for acute microbial pulmonary exposure
studies in mice (37). In previous work, the endotoxin-
sensitive CD-1 mouse model was used to determine health
effects following intranasal exposure (12). Because endo-
toxin is associated with gram-negative microorganisms, it is
necessary to use a model in which endotoxin-associated
effects are eliminated. In this study, 50% lethal doses (LD50)
of environmental and clinical pseudomonad isolates were
determined when possible and compared in endotoxin-resis-
tant and -sensitive mice. In an attempt to eliminate endo-
toxin effects, endotoxin-resistant mouse strain C3H/IeJ was
used to examine clearance and the pulmonary inflammatory
response following intranasal exposure to the pseudomon-
ads.
MATERIALS AND METHODS
Chemicals. All chemicals used in this study were reagent
grade and were obtained commercially. Methoxyfluorane
was obtained from Pittman-Moore, Mundelein, Ill. The
antibiotics kanamycin sulfate and ampicillin (sodium salt)
were purchased from Sigma Chemical Co., St. Louis, Mo.
Bacterial strains. The Pseudomonas spp. strains used in
this study are listed in Table 1. P. aeruginosa BC16, BC17,
and BC18 and P. maltophilia BC6 were isolated from a
commercial product (Sybron BiChem DC1006) designed for
Aroclor 1260 degradation (11). P. aeruginosa AC869 was
engineered to utilize 3,5-dichlorobenzoate as a sole carbon
and energy source and was kindly provided by A. M.
Chakrabarty, University of Illinois College of Medicine,
Chicago (8). P. aeruginosa PAO1 and DG1, both of which
are known to express many of the P. aeruginosa-associated
pathogenicity factors, were gifts from D. E. Woods, Univer-
sity of Calgary Health Sciences Centre, Calgary, Alberta,
Canada (17, 47). Strain AC869 was grown at 30°C. All other
cultures were incubated at 37°C.
Media and buffers. The strains were grown in yeast
extract-tryptone broth (26) to prepare the suspensions used
for administration to mice. Enumeration of these suspen-
sions was done on yeast extract-tryptone agar (1.5%) follow-
ing dilution in Dulbecco phosphate-buffered saline (PBS)
(GIBCO Laboratories, Grand Island, N.Y.). The cells were
concentrated, washed, and diluted in PBS. To select for the
pseudomonads from lungs and nasal cavities, Pseudomonas
isolation agar (Difco Laboratories, Detroit, Mich.) was used
for growth of the pseudomonads on solid medium. This
medium was prepared according to the manufacturer's in-
structions and was supplemented with 50 p,g of kanamycin or
ampicillin per ml as indicated below and in Table 1.
Animals. Thirty-day-old male strain C3HeB/FeJ (endotox-
in-sensitive) and C3I/HeJ (endotoxin-resistant) mice were
obtained from The Jackson Laboratory, Bar Harbor, Maine
(40). Deionized water and food (Purina Rodent Chow 5001;
Purina Mills, Inc., St. Louis, Mo.) were provided ad libitum,
and the mice were housed in polycarbonate cages (five mice
per cage) with pine shavings. The animals were quarantined
for 10 days prior to treatment. The animals were weighed on
the day before treatment and daily thereafter.
Intranasal exposure. All of the animals used in this study
were treated as follows. Food was withheld for 16 h prior to
dose administration. The animals were anesthetized with
methoxyfluorane in a desiccator jar (inside diameter, 100
mm), and 50 ,ul of PBS or 50 ,ul of a cell suspension was
injected unilaterally into the nostril cavity by using a 2.54-
cm, 22-gauge feeding needle. The doses used are listed in
Table 1. LD50 was determined by treating five animals per
dose (four different doses were used). LD50 was calculated
from the slopes and y intercepts derived from a linear
regression analysis of the data.
Enumeration of administered bacterial strains obtained
from lungs and nasal cavities. At 3 h and 1, 2, 5, 7, 10, and 14
days following treatment, mice were sacrificed by CO2
asphyxiation and were dissected aseptically. A small inci-
sion was made in the trachea, and a 1-in. (2.54-cm) 22-gauge
feeding needle was introduced into the airway. Heavy thread
was tied around the trachea at the tip of the needle to prevent
leakage. A 10-ml syringe containing 5 ml of PBS was
connected to the needle, and the trachea was then back-
flushed with PBS. The liquid was collected from the nostrils.
Next, the lungs were removed and homogenized in 5 ml of
PBS. The homogenate, nasal wash, and dilutions of each
type of sample in PBS were plated for enumeration on
Pseudomonas isolation agar supplemented with the antibiot-
ics indicated in Table 1. Following incubation for 48 h and
counting, representative colonies were subcultured, and
antibiotic sensitivity was determined by using antibiotic
disks (BBL Microbiology Systems, Cockeysville, Md.) to
eliminate contaminants in the enumeration of the strain
administered. For each experiment three animals per treat-
ment per time point were used. Duplicate experiments were
performed; thus, a total of six animals per treatment per time
point were used.
Inflammatory response. C3H/HeJ mice were sacrificed by
injecting sodium pentobarbital (150 mg/kg) intraperitoneally
at 1, 2, 5, 7, and 14 days following treatment, and cells were
collected from the lungs by bronchoalveolar lavage. Each
trachea was cannulated, and the lungs were flushed three
times with warm saline (35 ml/kg). Cytospin preparations
were stained with Diff-Quick (Baxter Diagnostics, Inc.,
McGaw Park, Ill.), and the percentages of alveolar macro-
phages, polymorphonuclear leukocytes (PMNs), and lym-
phocytes were determined by examining 200 representative
cells. The inflammatory index was defined as the sum of the
percentage of PMNs and the percentage of lymphocytes. We
used four or five mice for each treatment-time combination.
Statistical analysis. A three-way analysis of variance was
performed to determine what effects treatment, time, and
experimental replicate had on animal weights, lung weights,
and the ratio of lung weight to body weight (35). Values were
considered significant if P was <0.005.
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RESULTS
Overt health effects following intranasal exposure of endo-
toxin-resistant and -sensitive mouse strains. Following treat-
ment, animals were observed for signs of illness, including
weight loss, scruffy fur, lethargy, and conjunctivitis. Be-
cause the food was removed 16 h prior to dose administra-
tion, all groups lost weight initially. After 1.48 x 109 CFU of
P. aeruginosa BC16 was administered to C3HeB/FeJ mice,
two animals died. The weights of the survivors increased
after 2 days. In C3H/HeJ mice, a weight increase occurred
after the day on which the dose was administered. None of
the strain BC17- or BC18-treated animals died (doses, 5.35 x
109 and 1.5 x 109 CFU, respectively), but a similar weight
recovery phenomenon occurred. The weight of C3H/HeJ
animals increased immediately, but the weight of the treated
C3HeB/FeJ animals increased after 4 days.
All of the mice died when animals were treated with 1.22
x 108 or 1.22 x 109 CFU of strain AC869 or with 1.14 x 108
or 1.14 x 109 CFU of strain DG1. The LD50 of strain AC869
was 1.05 x 107 CFU for both C3H/HeJ and C3Heb/FeJ mice.
When mice were treated with 1.22 x 108 CFU of strain
AC869 or 1.14 x 108 CFU of strain DG1, 100% mortality was
observed. The C3HeB/FeJ mice died within 24 h, but the
C3H/HeJ mice died after 3 days. However, when 1.22 x 109
or 1.14 x 109 CFU of strain AC869 or DG1 was adminis-
tered, all of the C3Heb/FeJ mice died within 24 h, but the
C3H/HeJ animals survived an additional 1 day. When
C3HeB/FeJ mice were treated with 1.14 x 107 CFU of strain
DG1, all of the animals died after 3 days, which corre-
sponded to the time when the weight of the one surviving
C3H/HeJ mouse increased. The LD50 of strain DG1 were
calculated to be 6.56 x 106 CFU for C3Heb/FeJ mice and
1.00 X 107 CFU for C3H/H3J mice. When treated with 1.22
x 107 CFU of strain AC869, three C3HeB/FeJ mice and
three C3H/HeJ mice died. The weights of the survivors
increased in two (C3H/HeJ) or three (C3HeB/FeJ) days.
Endotoxin-resistant and -sensitive mice were also treated
with P. aeruginosa PAO1 or P. maltophilia BC6 and ob-
served for signs of illness. The endotoxin-sensitive mice
appeared to be more resistant to the treatments. Weight loss
that led to death was always accompanied by scruffy fur and
lethargy. No conjunctivitis was observed. When C3HeB/FeJ
mice were given 1.6 x 108 CFU of strain BC6, one animal
died and the weights of the survivors increased after the day
on which treatment was administered. Two identically
treated C3H/HeJ mice died, and a weight increase occurred
after 2 days. Strain PAO1 (LD5O, 1.02 x 107 CFU for
C3Heb/FeJ mice and 2.75 x 107 CFU for C3H/HeJ mice)
was lethal within 24 h following treatment with 8.7 x 10
CFU. When C3H/HeJ mice were treated with 8.7 x 107 CFU
of strain PAO1, all of the animals were dead after 24 h,
whereas it took 3 days for death to occur in all of the
C3HeB/FeJ animals. All of the C3H/HeJ mice that received
8.7 x 106 CFU died within 3 days following treatment, but
only two of the C3Heb/FeJ mice died. The weights of the
remaining mice started to increase after day 4.
Clearance of administered strains from lungs and nasal
cavities. A nonlethal dose of each strain was administered
individually to C3HIHeJ animals, and then the mice were
monitored for 14 days following treatment (see Table 1 for
the doses used). Lung and nasal cavity contents were
examined. Only strain PAO1 was detected in both lungs and
nasal washes 14 days after treatment (Fig. 1). P. maltophilia
BC6 and P. aeruginosa BC16 and DG1 were recovered only
from the nasal cavities at the end of the experiment (Fig. 1).
P. aeruginosa BC17, BC18, and AC869 were not observed in
either lung or nasal cavity washes 14 days following treat-
ment (Fig. 1).
Pulmonary inflammatory response. One day following
treatment and at intervals thereafter for 14 days, cells were
collected from the lungs by bronchoalveolar lavage. The sum
of the percentage of PMNs and the percentage of lympho-
cytes was determined. A strong response (or high response
index) was observed in animals treated with P. aeruginosa
AC869, PAO1, and DG1 (Fig. 2C). An intermediate response
was observed in mice treated with strains BC6, BC16, and
BC17 (Fig. 2B). No response was observed in strain BC18-
treated animals or PBS controls (Fig. 2A). In general, the
inflammatory responses consisted mainly of PMNs (data not
shown).
Effect of treatment on body and lung weights. At the time of
sacrifice, the animals were weighed and their lungs were
removed and weighed. An initial decrease in body weight
was observed for all animals because of the 16-h fasting
period prior to treatment. However, no treatment effect on
body weight was observed when data were compared with
data for PBS-treated controls. A statistical analysis revealed
that treatment with strain AC869 (overall) and treatment
with strain BC6 (3 h only) had an effect on lung weight. In
order to take body weight into account because lung weight
is a function of total body weight, statistical analyses were
performed on ratios of lung weight to body weight. Similar
results were obtained. Treatment with strain AC869 caused
an overall significant increase in the ratio of lung weight to
body weight (Fig. 3), whereas a decrease in this ratio was
observed at 3 h after treatment with strain BC6.
DISCUSSION
Because biotechnology agents are released in high num-
bers compared with organisms normally found in the envi-
ronment, there is a potential for human exposure and con-
sequent adverse effects. However, the organisms must be
able to survive the stress that occurs during application. For
example, during aerosolization, bacterial survival may be
impaired depending on the relative humidity, temperature,
distance traveled, droplet size, and UV radiation (32, 43).
After accidental release or planned application, humans may
ingest, inhale, or have dermal contact with engineered
microorganisms (21). Illness or an allergic reaction may
occur, especially if the immune system is impaired. Pulmo-
nary response to an endotoxin is associated with an influx of
erythrocytes, PMNs (which release elastase and serum
components), and the release of tumor necrosis factor (25,
44). Therefore, it is not surprising that pulmonary exposure
to both environmental P. aeruginosa isolates (BC16, BC17,
and AC869) and clinical P. aeruginosa isolates (PA01 and
DG1) results in an influx of PMNs. Toews et al. (41)
demonstrated that the cell response was challenge species
specific. For example, Staphylococcus aureus challenge
resulted in an increase in the number of alveolar macro-
phages, while an increase in the number of PMNs occurred
after P. aeruginosa treatment. Kiebsiella pneumonia caused
PMN and alveolar macrophage responses. In this study, the
intensity of the inflammatory response was strain dependent.
Our data indicate that an environmental isolate, strain
AC869, and two clinical strains, DG1 and PAO1, induced
relatively strong inflammatory responses which were in-
versely correlated with decreases in the number of bacterial
cells in the lungs.
According to the breeder, endotoxin resistance is associ-
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FIG. 3. Effect of P. aeruginosa AC869 treatment on the ratio of
lung weight to body weight. Strain C3H/HeJ mice were treated with
1.74 x 106 CFU of strain AC869 per mouse (cross-hatched bars),
and lungs were removed at the times indicated and weighed. The
ratio of lung weight to body weight was calculated and statistically
analyzed. An overall treatment effect was observed in strain AC869-
challenged mice (P = 0.0001). The control animals (solid bars) each
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2 4 68 10 12 ~ peared to be more tolerant to challenge with these strains. It
DAY
14
should be noted that both C3H/HeJ and C3HeB/FeJ miceDAY C died when they were treated with the higher concentrations
of P. aeruginosa AC869 (1.22 x 108 and 1.22 x 109 CFU),
PAO1 (8.7 x 107 and 8.7 x 108 CFU), and DG1 (1.14 x 108
and 1.14 x 109 CFU).
STRONG RESPONSE Clearance of pseudomonads from lungs has been shown to
be strain, host, and dose dependent. Progressive clearance,
multiplication followed by clearance, or persistence can
occur following challenge with P. aeruginosa (38). For
example, when BALB/c mice were treated with 8 x 104 CFU
of a P. aeruginosa clinical isolate, the organism was rapidly
__ -__ -- cleared from the lungs 4 h after introduction. However, at a
8'1|* ' * ' * ' higher dose (6 x 105 CFU) multiplication in the lungs2 4 6 D 12 14 occurred after 4 h (41). When white Swiss mice were
DAY
exposed to aerosols of P. aeruginosa 16 (1.85 x 105 CFU
ilmonary inflammatory response index. Four or five deposited in lungs immediately after exposure) or P. aerug-
acrificed at different times after treatment, and cells inosa 22 (2.65 x 105 CFU deposited in the lungs immediately
d from the lungs by bronchoalveolar lavage. Cytospin after exposure), the organisms multiplied within 1 h after
were stained with Diff-Quick, and the percentages of exposure (39). By 4 h, only 13% of the P. aeruginosa 16 cells
rophages, PMNs, and lymphocytes were determined by remained. P. aeruginosa 22 persisted at a level that was 97%
)0 representative cells. The inflammatory index was of the original dose. The results were different in experi-
sum of the percentage of PMNs and the percentage of ments performed with rats. When 1.95 x 106 CFU of strain(A) No response. Symbols: *, PBS control; A, 1.2 x 16 or410x0'CUostrain22 x 10 in of lungs,P. aeruginosa BC18 per mouse. (B) Intermediate 16 or 4.10 x 106 CFU of strain 22 was deposited in the lungs,
mbols: *, 2.0 x 106 CFU of P. maltophilia BC6 per both strains were cleared by 4 h (the levels after 4 h were 4.9
)xl106CFU of P. aeruginosa BC16 per mouse; @, 1.2 and 5.5% of the original levels). In order to produce a
f P. aeru,&inosa BC17 per mouse. (C) Strong response. chronic P. aeruginosa infection in rat lungs, the organism
1.4 x 10 CFU ofP. aeruginosa AC869 per mouse; A, can be embedded in agar beads (6).
U of P. aeruginosa PAO1 per mouse; 0, 1.5 x 106 CFU In this study, clearance was strain and species dependent.
rosa per mouse. Progressive clearance of P. maltophilia BC6 occurred fol-
lowing microbial challenge. The organism was cleared from
the lungs within 10 days, whereas P. aeruginosa BC16,
3H/HeJ mice (40). Therefore, endotoxin-resistant BC17, and BC18 were not detected after 5 (BC16 and BC18)
nice were used in this study to eliminate the and 7 (BC17) days. Strain AC869 was cleared by 14 days
iffects, even though there appeared to be little after treatment. Clinical isolate DG1 was cleared from the
etween C3HeB/FeJ and C3H/HeJ mice. Endo- lungs by day 5, but strain PAO1 was detected in lungs 14
ant mice appeared to be more resistant to overt days following challenge. Colonization of the nasal cavity
effects, such as weight loss, when they were may cause reinoculation of the lungs. For all of the strains
i strains BC16, BC17, BC18, AC869, and DG1. tested, the organisms detected in the nasal cavity also were
he results of the animal treatment experiments isolated from the lungs. Most of the organisms persisted
with strains PAO1 and BC6 were unexpected longer in the nasal cavity; the only exception was strain





































14 days following treatment. Strain PA01 was not detected
in the nasal cavity at day 7 and was recovered in low
numbers 10 and 14 days following treatment. The level of
recovery from the lungs was low as well. The apparent
rebound effect may have been due to low, nondetectable
concentrations of strain PAO1 in the nasal cavity followed
by a regrowth phase to detectable levels at later time points.
Because the bacterial counts were close to the limit of
detection, animal-to-animal variation may have played a role
in the inability to recover strain PA01 on day 7.
Even though most clearance studies have been conducted
with clinical isolates, several investigators have examined
pulmonary exposure to environmental isolates. Goodnow et
al. (14) exposed Sprague-Dawley rats to aerosols of a com-
mercial product for ice nucleation which contained P. syrin-
gae. A dose-dependent increase in lung weight was ob-
served. Kaiser et al. (18) performed a similar experiment
with P. putida C1 and Pseudomonas sp. strain CBSa. These
authors concluded that following exposure, no adverse ef-
fects were observed. Dose-dependent clearance of P. aerug-
inosa AC869 from CD-1 mice has been reported (12). In this
model system, an LD50 of 2.7 x 107 CFU was reported. The
organism was not detected 10 days after treatment, which is
a shorter time than the time observed in the endotoxin-
resistant C3HIHeJ mouse model. P. cepacia AC1100, which
degrades 2,4,5-trichlorophenoxyacetic acid, caused an in-
crease in lung weight following exposure of animals to 5.3 x
108 CFU of this organism (12); this was similar to the results
obtained for strain AC869.
Adverse effects from human exposure to bacteria and
endotoxins in agricultural and industrial settings have been
well documented (7, 34), but there have been few studies of
biotechnology products. However, in one study workers
found that the endotoxin concentration in a snow inducer
product (P. syringae in pellets) was 50,304.84 endotoxin
units/ml, which was more than 100-fold higher than the
concentration found in oats in a grain storage bin and in corn
silage, which have been linked to respiratory dysfunction
(10, 31). In addition to the endotoxin hazard, the bioengi-
neering process may alter the expression of virulence fac-
tors, resulting in a strain that is more or less pathogenic.
Consequently, there may be a potential for adverse health
effects due to exposure to biotechnology products. Our
results indicate that clearance from lungs, animal illness, and
death are strain dependent.
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